Abstract
Although proteomics is a very recently developed science, important advances have already occurred in this field. There is growing interest in the scientific community for using this technology as a high-throughput innovative strategy for biomarker discovery in the field of cancer research. However, certain challenges must be overcome before reaching this goal. The basis for discovering reliable biomarkers is rooted in technical and biological parameters. The main biological limit is outlining tumor heterogeneity, while methodological issues include appropriate study designs, the use of sensitive technologies for screening, and the employment of confident strategies for data validation. This review focuses on the major questions related to the strengths and limitations of the development of cancer biomarkers by proteomic- based studies.
Keywords: Biomarkers, cancer, design of studies, mass spectrometry, proteomics, tumor heterogeneity.
Current Proteomics
Title:How can Proteomics Reach Cancer Biomarkers?
Volume: 10 Issue: 2
Author(s): Carolina Panis, Luciana Pizzatti and Eliana Abdelhay
Affiliation:
Keywords: Biomarkers, cancer, design of studies, mass spectrometry, proteomics, tumor heterogeneity.
Abstract: Although proteomics is a very recently developed science, important advances have already occurred in this field. There is growing interest in the scientific community for using this technology as a high-throughput innovative strategy for biomarker discovery in the field of cancer research. However, certain challenges must be overcome before reaching this goal. The basis for discovering reliable biomarkers is rooted in technical and biological parameters. The main biological limit is outlining tumor heterogeneity, while methodological issues include appropriate study designs, the use of sensitive technologies for screening, and the employment of confident strategies for data validation. This review focuses on the major questions related to the strengths and limitations of the development of cancer biomarkers by proteomic- based studies.
Export Options
About this article
Cite this article as:
Panis Carolina, Pizzatti Luciana and Abdelhay Eliana, How can Proteomics Reach Cancer Biomarkers?, Current Proteomics 2013; 10 (2) . https://dx.doi.org/10.2174/1570164611310020006
DOI https://dx.doi.org/10.2174/1570164611310020006 |
Print ISSN 1570-1646 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6247 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Fragile X Family of Disorders: A Model for Autism and Targeted Treatments
Current Pediatric Reviews Advances in the Treatment of Ovarian Cancer Using PARP Inhibitors and the Underlying Mechanism of Resistance
Current Drug Targets The Promise of Dolutegravir: A Novel Second Generation Integrase Strand Transfer Inhibitor
Current Clinical Pharmacology Third Generation Radiopharmaceuticals for Imaging and Targeted Therapy
Current Pharmaceutical Analysis The Role of Estrogen and Estrogen-Related Drugs in Cardiovascular Diseases
Current Drug Metabolism A Review of Therapeutic Effects of Curcumin
Current Pharmaceutical Design A Friend in Need May Not be a Friend Indeed: Role of Microglia in Neurodegenerative Diseases
CNS & Neurological Disorders - Drug Targets Anti-Cancer Agent-Induced Nephrotoxicity
Anti-Cancer Agents in Medicinal Chemistry Chemotherapeutic Effects of Acridine Derivatives
Medicinal Chemistry Reviews - Online (Discontinued) Role of ABC Transporters in Veterinary Medicine: Pharmaco- Toxicological Implications
Current Medicinal Chemistry Vascular Disrupting Agents (VDA) in Oncology: Advancing Towards New Therapeutic Paradigms in the Clinic
Current Drug Targets Natural Compounds Containing a Condensed Cyclopropane Ring. Natural and Synthetic Aspects
Current Organic Chemistry Comparison of Triflusal with Aspirin in the Secondary Prevention of Atherothrombotic Events; Α Randomised Clinical Trial
Current Vascular Pharmacology Patents on Immunotoxins and Chimeric Toxins for the Treatment of Cancer
Recent Patents on Drug Delivery & Formulation Insight to Physiology and Pathology of Zinc(II) Ions and Their Actions in Breast and Prostate Carcinoma
Current Medicinal Chemistry Methotrexate: Should We Start Using it in Clinical Practice?
Current Drug Targets TRAIL Gene Therapy: From Preclinical Development to Clinical Application
Current Gene Therapy Antitumor Potential and Possible Targets of Phenothiazine-Related Compounds
Current Drug Targets Modulation of intracellular pH in human ovarian cancer.
Current Molecular Medicine The Effect of Bitter Melon (Momordica charantia) Extract on the Uptake of <sup>99m</sup>Tc Labeled Paclitaxel: In Vitro Monitoring in Breast Cancer Cells
Anti-Cancer Agents in Medicinal Chemistry